Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2014 /
New drug OTX15 shows early promise in fighting acute myeloid leukaemia

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.14
Views: 2831

Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland

Dr Cvitkovic talks to ecancertv at the AACR conference about the Phase I clinical trial of OTX015, in patients with haematologic malignancies including acute myeloid leukaemia.

OTX15 works by inhibiting BET bromodomain proteins 2/3/4, which play a significant part in the growth of cancer cells. Cvitkovic hopes to expand the study to look at its use in solid tumours in the near future.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence